The Motley Fool··Prosper Junior BakinyInovio Pharmaceuticals Faces Regulatory Headwinds Amid Capital Constraints
Inovio Pharmaceuticals faces FDA rejection of its lead drug candidate and mounting cash constraints, raising questions about the biotech firm's long-term viability without revenue-generating products.
INOFDA approvalbiotech